Mounjaro (tirzepatide) works by activating two hormone receptors at once, mimicking natural gut hormones that regulate blood sugar, appetite, and fat storage. It’s the first drug in its class to target both GIP and GLP-1 receptors, which gives it a distinct edge over older medications that only target one. This dual action is why Mounjaro produces some of the largest reductions in weight and blood sugar seen in clinical trials to date.
Two Gut Hormones, One Molecule
Your body naturally produces two hormones after you eat: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both help manage blood sugar by signaling your pancreas to release insulin when glucose levels rise. Mounjaro is a synthetic molecule designed to activate the receptors for both of these hormones simultaneously, but it doesn’t treat them equally.
Tirzepatide binds to GIP receptors with the same strength as your body’s own GIP, making it a full-strength activator there. At the GLP-1 receptor, it’s more selective. It binds about five times more weakly than natural GLP-1 and acts as a partial activator, reaching roughly 51% of the signaling strength of the natural hormone. This imbalance is intentional. At the GLP-1 receptor, tirzepatide preferentially triggers the signaling pathway that leads to insulin release while largely avoiding a secondary pathway (called beta-arrestin recruitment) that pulls receptors off the cell surface. The result is that GLP-1 receptors stay active longer rather than getting pulled inside the cell and shut down, which may explain why even partial activation still produces strong clinical effects.
How It Reduces Appetite
Much of Mounjaro’s weight loss effect comes from changes in how hungry you feel and how quickly your stomach empties. The GLP-1 side of the drug slows the movement of food from your stomach into your small intestine. When food sits in your stomach longer, you feel full faster during meals and stay satisfied for a longer stretch afterward. Less glucose also enters your bloodstream at once, which helps prevent the sharp blood sugar spikes that can drive cravings.
The drug also acts directly on the brain. GLP-1 receptors in the hypothalamus, the brain’s appetite control center, respond to tirzepatide by turning up neurons that produce fullness signals and turning down neurons that drive hunger. This creates a sustained reduction in appetite that goes beyond just feeling physically full. Many people on Mounjaro describe a quieting of food-related thoughts, less interest in snacking, and an easier time stopping when satisfied.
What the GIP Receptor Adds
Older drugs like semaglutide (Ozempic, Wegovy) only target GLP-1. Mounjaro’s activation of GIP receptors adds a layer of metabolic benefits, particularly in fat tissue. GIP receptor activation enhances insulin signaling in fat cells, helping them take up glucose and fatty acids from the bloodstream more efficiently after meals. In animal studies, a long-acting GIP receptor activator reduced circulating triglyceride levels during fat digestion and increased the uptake of dietary fatty acids into fat tissue, essentially improving how the body handles and stores dietary fat.
GIP activation also appears to make fat tissue more metabolically flexible. In the fed state, when insulin is high, GIP cooperates with insulin to clear glucose and fat from the blood. In the fasted state, when insulin drops, GIP signaling shifts to support fat release for energy. This dual role means fat cells respond more appropriately to the body’s changing energy needs throughout the day rather than staying locked in storage mode or release mode. Research in Cell Metabolism showed that GIP receptor activation substantially altered the expression of genes governing fat metabolism, sugar processing, and energy production in fat cells.
Weight Loss Results
The SURMOUNT-1 trial, the landmark obesity study, tested Mounjaro against placebo in over 2,500 adults with obesity or overweight. After 72 weeks, the results were striking. Participants on the 5 mg dose lost an average of 15% of their body weight. The 10 mg group lost 19.5%, and the 15 mg group lost 20.9%. The placebo group lost 3.1%. To put that in perspective, for someone weighing 250 pounds, the highest dose translated to roughly 52 pounds lost over about a year and a half.
These numbers exceeded what had been seen with GLP-1-only drugs at the time, suggesting the dual receptor approach provides additional benefit beyond GLP-1 activation alone.
Effects on Blood Sugar
For people with type 2 diabetes, Mounjaro’s original approved use, the drug lowers blood sugar through several overlapping mechanisms. It stimulates insulin release from the pancreas, but only when blood sugar is elevated, which reduces the risk of dangerous blood sugar drops. It also suppresses glucagon, a hormone that tells the liver to dump stored sugar into the bloodstream. Slower stomach emptying further smooths out post-meal glucose spikes. Across the SURPASS clinical trials in type 2 diabetes, tirzepatide consistently produced significant reductions in A1c, the marker that reflects average blood sugar over two to three months.
Cardiovascular Effects
Early evidence suggests Mounjaro may benefit heart health. A retrospective study published in JACC: Advances found that people taking tirzepatide had a 40% lower rate of a combined outcome of heart attack, stroke, and death compared to those on GLP-1 receptor agonists alone. A meta-analysis of the SURPASS diabetes trials also showed a trend toward fewer major cardiovascular events, though those trials weren’t designed to definitively answer that question. A dedicated cardiovascular outcomes trial is expected to report results in 2025.
Dosing and What to Expect
Mounjaro is a once-weekly injection given under the skin, typically in the abdomen, thigh, or upper arm. You start at 2.5 mg for the first four weeks. This starting dose isn’t meant to control blood sugar or produce significant weight loss on its own. It’s a ramp-up period to let your body adjust and reduce side effects. After four weeks, the dose increases to 5 mg. From there, your doctor may increase the dose in 2.5 mg steps every four weeks or longer, up to a maximum of 15 mg per week, depending on how you respond and what you can tolerate.
The gradual titration matters. Most side effects are dose-related and more likely during increases, so rushing the schedule tends to make the experience rougher without improving outcomes.
Common Side Effects
Gastrointestinal symptoms are by far the most frequent issue. In the diabetes trials (SURPASS-1 through SURPASS-5), nausea affected 12% to 24% of participants, diarrhea 12% to 22%, and vomiting 2% to 13%. The obesity trial (SURMOUNT-4) showed higher rates: nausea at 35.5%, diarrhea at 21.1%, constipation at 20.7%, and vomiting at 16.3%. Most of these symptoms are mild to moderate and tend to be worst during dose increases, improving over time as the body adjusts.
Eating smaller meals, avoiding high-fat or greasy foods, and staying hydrated can help manage nausea during the adjustment period. Some people find that certain doses are their ceiling, where the side effects of going higher outweigh the additional benefit.
Safety Considerations
Mounjaro carries an FDA black box warning, the most serious type, regarding thyroid tumors. In rats, tirzepatide caused thyroid C-cell tumors at doses comparable to those used in humans, and the risk increased with higher doses and longer treatment. Whether this translates to humans is unknown. As a precaution, Mounjaro is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. Symptoms to be aware of include a lump in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness.
Mounjaro can also cause pancreatitis in rare cases, and it is not recommended for people with a history of severe gastrointestinal disease. Because it affects stomach emptying, it may change how quickly your body absorbs oral medications, which is worth discussing with a prescriber if you take other drugs on a tight schedule.